Microbix Biosystems Inc. announces the commercial launch of QUANTDx™, a new product line of well-characterized reference materials designed to support the development and validation of diagnostic assays.

Microbix Biosystems Inc. will be attending, exhibiting, and presenting at the Association for Diagnostic & Laboratory Medicine (“ADLM”) conference taking place in Chicago, Illinois July 28 to 31, 2025.

Microbix Biosystems Inc. and the National Center for Infectious and Parasitic Diseases of Bulgaria (“NCIPD”), announce an agreement whereby NCIPD will supply a portfolio of pathogen seedstocks for production of Microbix quality assessment products (“QAPs™”).

Microbix Biosystems Inc. announces that it is attending and presenting at the 2nd Asia Pacific Conference on Point of Care Testing for Infectious Diseases, taking place in Bangkok, Thailand from 19 to 21 June, 2025 (“POC2025”).

In Ontario, health expenditures now exceed $87 billion per year and comprise over 40 per cent of overall spending. Such expenses are growing faster than our per capita productivity and show no signs of slowing down.

Microbix reports results for its second quarter and first half of fiscal 2025 ended March 31, 2025 (“Q2” and “H1”). Sales for Q2 and H1 reflected differential growth between Antigens (up) and QAPs™ (down), alongside a markedly-improved gross margin.

Microbix & Aurevia announce a pilot external quality assessment (“EQA”) program to help clinical laboratories establish their proficiency at using molecular diagnostic methods (e.g., PCR tests) to diagnose bacterial vaginosis (“BV”).

Microbix announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2025 ended March 31, 2025 (“Q2 2025”) prior to the start of trading on May 15, 2025.

Microbix announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the formulated and packaged drug (i.e., “Drug Product”) of Kinlytic® urokinase (“Kinlytic”), a biologic drug for dissolving blood clots.

announces it will be attending and presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, North Building, on Monday and Tuesday, May 5 & 6, 2025.